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Purpose: We examined the prevalence and risk of clinical symptoms in a large number of Japanese pa-
tients with Parkinson’s disease (PD) (n ¼ 1453; 650 males).
Methods: Events were analyzed using KaplaneMeier survival curves, logistic regression, and Cox
proportional-hazards models.
Results: The mean age (SD) was 67.7 (10.0), age of onset was 58.0 (11.5), and disease duration was 9.7
(6.6) years. The mean modiﬁed Hoehn and Yahr stage was 2.8 (1.2). Most patients (88.9%) received
levodopa (547.7 (257.6) mg/day). A large proportion (81.3%) received dopamine agonists (136.2 (140.7)
mg/day). About 23.4% received pain treatment 6.9 (5.1) years after the onset; females (p < 0.05) and
patients with late-onset PD (60 years, p < 0.001) were more likely to be affected. About 44.7% of pa-
tients had wearing-off 7.5 (4.7) years after the onset, and it was more common in females (p < 0.001) and
patients with early-onset PD (p < 0.001). Camptocormia was found in 9.5% of patients 8.1 (6.2) years after
the onset, and it was more common in females (p < 0.05) and patients with late-onset PD (p < 0.05).
About 28.6% of patients developed psychosis 9.0 (5.4) years after the onset, and it was more likely to
occur in patients with late-onset PD (p < 0.001). Late-onset PD and cerebrovascular disease were also
associated with increased risk of pneumonia.
Conclusions: Considering that very few studies have assessed numerous clinical symptoms in the same
report, these data provide a useful reference for the clinical course of PD.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Parkinson’s disease (PD) is the second most common neuro-
degenerative disorder after Alzheimer’s disease. Dopamine, Juntendo University Koshi-
apan. Tel.: þ81 48 975 0321;
yahoo.co.jp (A. Yoritaka).
BY-NC-ND license.replacement with levodopa or dopamine agonists (DA) results in
marked improvement of motor symptoms and alleviation of
disability; these treatments have also improved patient survival
[1,2]. However, levodopa use is also associated with the devel-
opment of motor complications that substantially contribute to
disability in patients with advanced PD. Various motor and non-
motor symptoms (NMS) and side effects of anti-parkinsonian
drugs limit the medication dose and the ability to prescribe
other drugs. Here, we have described the prevalence and risk
Table 1
Baseline demographic and clinical characteristics of patients with Parkinson’s disease.
Variable Category n or mean SD Median
Total 1453
Age 67.7 10.0 68.5
Age at onset 58.0 11.5 59.3
Sex Male 650 (44.7%)
Female 803 (55.3%)
Disease duration Mean 9.7 6.6 8.5
Hoehn and Yahr stage on First visit Enrollment
0 10 (0.7%) 48 (3.3%)
0.5 and 1.0 241 (16.6%) 101 (7.0%)
1.5 and 2.0 685 (47.1%) 428 (29.5%)
2.5 and 3.0 414 (28.5%) 438 (30.1%)
4 68 (4.7%) 294 (20.2%)
5 10 (0.7%) 99 (6.8%)
Not described 25 (1.7%) 45 (3.1%)
Hypertension 258 (17.8%)
Dyslipidemia 174 (12.0%)
Diabetes mellitus 79 (5.4%)
Cerebral vessel disease 86 (5.9%)
Malignant tumor 87 (6.0%)
Therapy in another hospital before our hospital 802 (55.2%)
Anti-parkinsonian drugs
Levodopa 1292 (88.9%)
Duration from onset to start of treatment Years 2.9 3.2 2.0
Daily dose at enrollment day mg 547.7 257.6 600.0
Cumulative dose g 1259.2 1190.0 933.4
Pramipexole 900 (61.9%)
Duration from onset to start of treatment Years 6.4 5.6 5.0
Daily dose (n ¼ 900) mg 2.1 2.6 1.7
Ropinirole 212 (14.6%)
Duration from onset to start of treatment Years 7.5 6.1 6.0
Daily dose (n ¼ 212) mg 7.5 4.7 3.3
Pergolide 414 (28.5%)
Duration from onset to start of treatment Years 4.9 4.9 3.5
Daily dose (n ¼ 414) mg 941.4 2.0 1.6
Cabergoline 405 (27.9%)
Duration from onset to start of treatment Years 4.9 5.2 3.3
Daily dose (n ¼ 405) mg 2.3 1.3 2.0
Bromocriptine 99 (6.8%)
Duration from onset to start of treatment Years 4.3 4.2 3.4
Daily dose (n ¼ 99) mg 16.2 7.5
Dopamine agonist 1182 (81.3%)
Duration from onset to start of treatment Years 4.0 4.4 2.6
Daily dose (n ¼ 1453) mg 136.2 140.7 120.0
Entacapone 314 (21.6%)
Duration from onset to start of treatment Years 10.3 5.8 9.3
Daily dose (n ¼ 314) mg 490.3 249.3 400.0
Trihexyphenidyl 561 (38.6%)
Duration from onset to start of treatment Years 4.0 4.0 2.7
Daily dose (n ¼ 561) mg 3.3 1.6 3.0
Amantadine 598 (41.2%)
Duration from onset to start of treatment Years 5.6 5.8 3.9
Daily dose (n ¼ 598) mg 166.0 63.6 150.0
Zonisamide 98 (6.7%)
Duration from onset to start of treatment Years 9.9 7.2 8.2
Daily dose (n ¼ 98) mg 47.3 34.9 25.0
Droxidopa 134 (9.2%)
Duration from onset to start of treatment Years 7.0 5.1 5.9
Daily dose (n ¼ 134) mg 380.6 178.7 300.0
Selegiline 620 (42.7%)
Duration from onset to start of treatment Years 6.7 5.0 5.6
Daily dose (n ¼ 620) mg 7.2 6.0 5.0
A. Yoritaka et al. / Parkinsonism and Related Disorders 19 (2013) 725e731726of clinical symptoms in a large number of Japanese patients
with PD.
2. Patients and methods
Between January and June 2010, we retrospectively reviewed the charts of pa-
tients who had visited our outpatient neurology clinic at Juntendo Hospital in Tokyo,
and had been diagnosed with PD by a board-certiﬁed neurologist. Diagnoses were
based on the UK Brain Bank diagnostic criteria for PD [3], and patients with de-
mentia with Lewy bodies [4], progressive supranuclear palsy, corticobasaldegeneration, vascular parkinsonism, and other forms of parkinsonism were
excluded. Hospital charts were systematically reviewed by A.Y. This study was
approved by the Juntendo Hospital institutional ethics committee, and informed
consent was obtained.
The following data were collected from patients: sex; date of birth, ﬁrst visit,
and onset; initial symptoms, side of initial symptoms, order of medications taken
from the time of initial medication, approximate date of start or stop of each
medication, and modiﬁed Hoehn and Yahr (H & Y) stage for the initial and ﬁnal
evaluations; and dates of important events (pain, wearing-off, camptocormia, sleep
attack, orthostatic hypotension, psychosis, electrical convulsive therapy [ECT] for
severe psychosis, neuroleptic malignant syndrome, pneumonia, and tube feeding).
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sonism (bradykinesia, rest tremor, and/or rigidity). “Pain” was deﬁned as pain that
required treatment, including pain related to wearing-off and excluding pain
related to bone fracture, myocardial infarction, respiratory disease, and abdominal
disease. “Camptocormia” was deﬁned as marked anterior ﬂexion of the thor-
acolumbar spine in the recumbent position without evidence of ﬁxed kyphosis.
“Sleep Attack” was an acute and irresistible episode of sleep occurring without
warning signs [5]. “Orthostatic hypotension” was deﬁned as a greater than
20 mmHg decrease in systolic pressure. “Psychosis” included reports of illusion,
false sense of presence, hallucinations, or delusions that continued or recurred for
at least 1 month [6]. Diagnosis of “neuroleptic malignant syndrome” was based on
Levenson’s criteria [7]. Other NMS like depression, cognition, apathy, and excessive
daytime sleepiness were not selected, because their onset was not clear, and the
patients were not regularly examined using tools like the NMS questionnaire
(NMSQuest) [8], Scale for Outcomes in Parkinson’s Disease-Psychiatric Complica-
tions (SCOPA-PC) [9], or SCOPA-Cognition (SCOPA-COG) [10]. NMS in early PD like
REM sleep behavior disorder (RBD), olfactory dysfunctions, or constipation were
not analyzed.
The daily levodopa equivalent dose was calculated on the basis of the following
equivalences: 100 mg standard levodopa ¼ 10 mg bromocriptine ¼ 1 mg
pergolide ¼ 5 mg ropinirole ¼ 1 mg pramipexole [11].
2.1. Statistical analyses
SAS (ver. 9.1.3; SAS Institute Inc., Cary, NC, USA) and SPSS (ver. 16.1; SPSS Inc.,
Chicago, IL, USA) were used for statistical analyses. The data are presented as mean
(standard deviation [SD]) values for age, age at onset, H & Y stage of the “on” phase,
daily dose of drugs, and duration from the onset of PD for important events. H & Y
stages without parkinsonism symptoms in the “on” phase were considered as “0”.
Point prevalences were calculated, and KaplaneMeier (KeM) time-to-event curves
and log-rank tests were used to estimate the absolute risk of each event. The factors
chosen were as follows: onset age (early onset < 60 years or late onset  60 years),
sex, hypertension (HT), diabetes mellitus (DM), dyslipidemia (DL), cerebrovascular
disease (CVD), and malignant tumor. These were selected because they are the most
frequently seen diseases in the Japanese. Logistic regression was performed to
calculate odds ratios (ORs) with 95% conﬁdence intervals (CIs) for each event. CoxTable 2
KaplaneMeier survival of events in the patients with Parkinson’s disease.




Pain Total 1453 340 (23.4) 3.2% 7
Age of onset <60 711 178 (25.0) 1.6% 4
60 742 162 (21.8) 4.8% 9
Sex Male 650 133 (20.5) 2.5% 6
Female 803 207 (25.8) 3.7% 7
Wearing-off Total 1453 649 (44.7) 1.8% 9
Sex Male 650 253 (38.9) 1.3% 8
Female 803 396 (49.3) 2.2% 11
Camptocormia Total 1453 138 (9.5) 0.7% 2
Age of onset <60 711 80 (11.3) 0.7% 1
60 742 58 (7.8) 0.7% 4
Sex Male 650 47 (7.2) 0.2% 1
Female 803 91 (11.3) 1.1% 3
Sleep attack Total 1453 65 (4.5) 0.4% 1
Orthostatic hypotension Total 1453 95 (6.5) 0.5% 1
Age of onset <60 711 45 (6.3) 0.1% 0
60 742 50 (6.7) 0.8% 2
Hypertension e 1195 88 (7.4) 0.5% 1
þ 258 7 (2.7) 0.4% 0
Psychosis Total 1453 416 (28.6) 1.7% 5
Age of onset <60 711 207 (29.1) 0.7% 2
60 742 209 (28.2) 2.7% 9
Malignant syndrome Total 1453 32 (2.2) 0.1% 0
Diabetes mellitus e 1374 27 (2.0) 0.1% 0
þ 79 5 (6.3) 0.0% 0
Pneumonia Total 1453 63 (4.3) 0.1% 0
Age of onset <60 711 27 (3.8) 0.0% 0
60 742 36 (4.9) 0.1% 0
Cerebrovascular disease e 1367 51 (3.7) 0.1% 0
þ 86 12 (14.0) 0.0% 1
All events were analyzed with all factors. The factors were designed as follows, onset a
malignant tumor. Table indicates only factors with signiﬁcant differences. *: p < 0.05, **proportional-hazard modeling was used to calculate hazard ratios (HRs) and 95% CIs
for differences among subgroups embedded into the following variables: age at
onset, sex, order of drugs (levodopa or other anti-parkinsonism drugs), and duration
to the start of drugs (levodopa, other drugs, or all anti-parkinsonism drugs). Pro-
portional hazardswere assessedwith graph logelog plots. Statistical tests were two-
sided, and the signiﬁcance level was set at p < 0.05.
3. Results
We evaluated 1453 patients with PD (650 males) (Table 1). Their
mean age (SD) was 67.7 (10.0), age of onset was 58.1 (11.5), and
disease duration was 9.7 (6.6) years. The mean follow-up at our
hospital was 5.9 (5.7) years. Age and age at onset were 67.2 (10.2)
and 57.5 (11.8) years, respectively, for males and 68.3 (9.6) and 58.6
(11.2) years, respectively, for females. The mean H & Y stages were
2.2 (0.8) at the ﬁrst visit and 2.8 (1.2) at the ﬁnal evaluation. Pa-
tients with H & Y stages of 0, I (0.5 and 1.0), II (1.5 and 2.0), III (2.5
and 3.0), IV (4.0), V (5), and unknown (not described) were 3.3%,
7.0%, 29.5%, 30.1%, 20.2%, 6.8%, and 1.7%, respectively. The per-
centages of patients with PD who also had HT, DL, DM, CVD,
and malignant tumor were 17.8%, 12.0%, 5.4%, 5.9%, and 6.0%,
respectively.
Most patients (1292, 88.9%) received levodopa, and the average
daily dose at enrollment was 547.7 (257.6) mg/day. The average
levodopa doses for patients with H & Y stages of 0, I, II, III, IV, and V
were 504.2 (252.8) mg, 498.0 (283.5) mg, 511.5 (304.2) mg, 484.9
(303.8) mg, 461.9 (283.4) mg, and 475.3 (270.1) mg, respectively
(including unmedicated patients). In total, 1182 patients (81.3%)
also received DAs; the average equivalent dose at enrollment was
136.2 (140.7) mg/day. The equivalent DA doses were 134.4 (142.4)
mg, 136.9 (138.1) mg, 136.6 (139.0) mg, 140.8 (142.3) mg, 129.5n and prevalence: KaplaneMeier (%) Log-rank test
h year 6th year 8th year 10th year 12th year
62 965 760 583 426
.1% 13.2% 19.8% 25.0% 30.2% e
.4% 9.8% 15.1% 21.1% 25.5% P < 0.001***
.9% 16.9% 25.7% 29.4% 37.0%
.2% 11.7% 17.6% 21.0% 26.5% P ¼ 0.018*
.9% 14.5% 21.6% 28.0% 33.1%
.9% 22.7% 40.5% 50.9% 61.8% e
.5% 18.6% 34.5% 40.9% 52.9% P < 0.001***
.1% 26.0% 45.4% 58.8% 68.7%
.7% 5.2% 7.5% 9.3% 11.8% e
.5% 3.5% 5.5% 7.0% 10.0% P ¼ 0.034*
.1% 7.2% 9.9% 12.1% 13.4%
.6% 3.9% 6.4% 7.5% 9.1% P ¼ 0.010*
.6% 6.3% 8.5% 10.7% 13.9%
.3% 2.4% 4.4% 6.7% 10.5% e
.6% 3.0% 4.8% 6.0% 8.3% e
.4% 1.4% 2.5% 3.0% 5.3% P < 0.001***
.8% 4.9% 7.9% 10.5% 12.8%
.8% 3.4% 5.5% 6.8% 9.5% P ¼ 0.005**
.9% 0.9% 1.5% 2.3% 2.3%
.8% 11.1% 18.0% 25.6% 33.8% e
.5% 5.8% 11.2% 16.0% 22.1% P < 0.001***
.4% 17.2% 26.6% 39.8% 53.9%
.2% 0.3% 1.1% 2.2% 2.8% e
.2% 0.3% 1.1% 1.7% 2.4% P ¼ 0.032*
.0% 0.0% 2.0% 9.0% 9.0%
.2% 0.7% 1.5% 2.8% 3.3% e
.0% 0.3% 0.3% 0.6% 0.8% P < 0.001***
.5% 1.1% 3.1% 6.6% 7.9%
.2% 0.5% 1.0% 2.1% 2.7% P < 0.001***
.3% 4.1% 7.6% 11.7% 11.7%
ge, sex, hypertension, diabetes mellitus, dyslipidemia, cerebrovascular disease, and
: p < 0.01, ***: p < 0.001.
Table 3


























Pain Odds ratio 0.85 1.18 1.42 0.83 1.00 1.00 0.10 0.96 0.83
CI 0.66e1.08 0.92e1.51 1.08e1.87 0.65e1.06 0.87e1.15 1.00e1.00 1.00e1.00 0.92e1.01 0.60e1.16 NE
p 0.177 0.191 0.013* 0.128 0.996 <0.001*** 0.099 0.090 0.283
Wearing-off Odds ratio 0.97 0.97 2.13 1.00 0.93 1.00 1.00 0.99 1.28
CI 0.75e1.27 0.75e1.23 1.61e280 0.77e1.29 0.82e1.07 1.00e1.00 1.00e1.00 0.93e1.04 0.91e1.79 NE
p 0.840 0.815 <0.001*** 0.989 0.316 <0.001*** <0.001*** 0.592 0.156
Camptocormia Odds ratio 0.88 1.12 1.56 0.87 1.37 1.00 1.00 0.95 1.00
CI 0.68e1.14 0.86e1.45 1.07e2.28 0.68e1.12 1.13e1.66 1.00e1.00 1.00e1.00 0.88e1.02 0.63e1.57 NE
p 0.319 0.403 0.022* 0.278 0.002** 0.113 0.681 0.144 0.860
Sleep attack Odds ratio 0.98 1.00 0.60 NE 1.01 1.00 0.93 0.88 1.21 NE
CI 0.93e1.03 0.95e1.06 0.36e1.00 0.78e1.30 0.99e1.00 0.78e1.11 0.76e1.02 0.93e1.58
p 0.980 0.970 0.048* 0.967 0.889 0.434 0.101 0.151
Orthostatic
hypotension
Odds ratio 0.86 1.19 0.95 0.82 1.32 1.00 1.00 1.03 1.25 4.47
CI 0.66e1.11 0.91e1.54 0.60e1.51 0.64e1.05 1.03e1.69 1.00e1.00 1.00e1.00 0.97e1.09 0.71e2.21 1.01e19.75
p 0.235 0.200 0.826 0.117 0.028* 0.190 0.016* 0.386 0.433 0.048*
Psychosis Odds ratio 0.98 1.06 1.20 1.01 1.49 1.00 1.04 0.94 0.68
CI 0.91e1.05 0.98e1.14 0.79e1.81 0.94e1.08 1.21e1.88 1.00e1.00 0.96e1.13 0.88e1.00 0.41e1.14 NE
p 0.505 0.136 0.401 0.845 <0.001*** <0.001*** 0.360 0.061 0.144
CI: conﬁdence interval, *: p < 0.05, **: p < 0.01, ***: p < 0.001, NE: not examined.
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respectively (including unmedicated patients). Equivalent DA
doses in H & Y stages I and II were not signiﬁcantly different
between patients with wearing-off (159.8 (156.0) mg) and those
without wearing-off (131.6 (137.0) mg). The average levodopa
dose for H & Y stage I and II patients was 538.8 (214.6) mg with
wearing-off and 278.0 (247.4) mg without wearing-off; this dif-
ference was statistically signiﬁcant (p < 0.001). H & Y stage I and II
patients with psychosis were on higher doses of levodopa (535.9
(220.2) mg) compared to patients without psychosis (336.9 (263.5)
mg) (p < 0.001). The average DA dose was 119.5 (151.6) mg in pa-
tients with psychosis and 146.9 (143.3) mg in those without
(p > 0.05).
The onset of events was signiﬁcantly (p < 0.001) earlier in pa-
tients with late onset than in those with early onset (AdditionalTable 4
Cox proportional hazards models for clinical events in patients with Parkinson’s disease










Pain HR 1.02 1.26 0.93 0.95
95%CI 1.01e1.03 1.08e1.58 0.86e1.00 0.91e0.9
p <0.001*** 0.043* 0.059 0.01*
Wearing off HR 0.99 1.46 0.89 0.97
95%CI 0.98e0.99 1.24e1.71 0.84e0.94 0.95e0.9
p <0.001*** <0.001*** <0.001*** 0.006**
Camptocormia HR 1.02 1.46 1.01 0.94
95%CI 1.01e1.04 1.03e2.08 0.90e1.12 0.88e1.0
p 0.012* 0.033* 0.909 0.053
Sleep attack HR 1.02 0.55 0.89 0.85
95%CI 0.99e1.05 0.33e0.90 0.75e1.05 0.74e0.9
p 0.085 0.017* 0.152 0.021*
Orthostatic
hypotension
HR 1.04 0.87 0.93 1.03
95%CI 1.02e1.06 0.57e1.34 0.79e1.09 0.98e1.0
p 0.001** 0.532 0.345 0.332
Psychosis HR 1.05 1.04 0.99 0.97
95%CI 1.04e1.07 0.85e1.26 0.93e1.06 0.94e1.0
p <0.001*** 0.714 0.781 0.096
Malignant
syndrome
HR 1.05 0.73 0.94 1.01
95%CI 0.99e1.06 0.35e1.53 0.74e1.21 0.93e1.0
p 0.176 0.404 0.646 0.883
Pneumonia HR 1.13 0.63 1.07 0.99
95%CI 1.09e1.16 0.83e1.06 0.91e1.26 0.93e1.0
p <0.001*** 0.083 0.435 0.771
HR: hazard rate, CI: conﬁdence interval, *: p < 0.05, **: p < 0.01, ***: p < 0.001, NE: notTable 1S). The prevalence and mean duration of each symptom
from onset of PD are shown in Additional Fig. 1. The data obtained
from KeM curves, logistic regression, and Cox HRs are shown in
Tables 2e4, respectively.
3.1. Pain
About 23.4% of patients had pain at a mean duration of 6.94
(5.12) years from PD onset. In the twelfth year, 37.0% of late-onset
and 25.5% of early-onset patients reported pain (p < 0.001); there
was a statistically signiﬁcant sex difference (p < 0.05). Logistic
regression showed that the pain OR was 1.42 (95% CI, 1.08e1.87;
p < 0.05) for females. Cox modeling yielded an HR of 1.26 (95% CI,
1.08e1.58; p < 0.05) for females and 1.02 (95% CI, 1.01e1.03;












9 0.79e1.41 NE NE NE
0.701
0.86
9 0.70e1.04 NE NE NE
0.123
1.08
0 0.70e1.68 NE NE NE
0.723
1.20
8 0.93e1.53 NE NE NE
0.160
0.94 1.63
8 0.53e1.66 0.97e2.74 NE NE
0.834 0.063
1.16
1 0.90e1.51 NE NE NE
0.253
2.05 2.47
9 0.70e6.01 NE 0.87e6.97 NE
0.189 0.088
2.00 1.98
5 0.93e4.29 NE NE 1.03e3.80
0.076 0.041*
examined.
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About 44.7% of patients experienced wearing-off an average of
7.52 (4.66) years after PD onset. The prevalence of dyskinesia was
27.1%, and all of these patients had wearing-off. Wearing-off was
more common in females (p < 0.001); 58.8% of female and 40.9% of
male patients had experienced it by the tenth year. Logistic
regression analysis revealed a signiﬁcantly higher OR for female
sex, daily dose of levodopa, and disease duration to the start of
levodopa. HRs were 1.46 (95% CI, 1.24e1.71; p < 0.001) for female
sex, 0.99 (95% CI, 0.98e0.99; p < 0.001) for age at onset, 0.89 (95%
CI, 0.84e0.94; p < 0.001) for disease duration to the start of levo-
dopa, and 0.97 (95% CI, 0.95e0.99; p < 0.01) for the duration to the
start of other drugs.
3.3. Camptocormia
Camptocormia was found in 9.5% of patients an average
of 8.05 (6.16) years after PD onset. Prevalence was higher in
late-onset patients than in early-onset patients (p < 0.05), and
more females developed the symptom (p < 0.01). Logistic
regression analysis revealed signiﬁcantly higher ORs for female
sex and higher H & Y stages. HRs were 1.02 (95% CI, 1.01e1.04;
p < 0.05) for age at onset and 1.46 (95% CI, 1.03e2.08; p < 0.05)
for female sex. In 34 patients, we stopped pramipexole and their
camptocormia improved; therefore, we also assessed campto-
cormia risk in patients who did or did not receive non-ergot DAs.
Among patients who received pramipexole, females showed a
higher prevalence of camptocormia (7.7% in the second year and
14.8% in the fourth year), and males had lower prevalence in the
early stage of disease (3.8% in the second year, 6.5% in the fourth
year) (p < 0.01). The HRs for patients on pramipexole were 1.82
(95% CI, 1.21e2.72; p < 0.001) for female sex and 0.67 (95% CI,
0.54e0.83; p < 0.001) for disease duration. For those who
experienced camptocormia without non-ergot DAs, no differ-
ences were observed for age at onset, sex, or accompanying
disease.
3.4. Sleep attack
An average of 8.50 (6.52) years from PD onset, 4.5% of patients
had sleep attack without warning signs. Daily DA doses were not
correlated to the prevalence of sleep attack. Logistic regression
analysis revealed signiﬁcantly higher ORs for male sex. HRs were
0.60 (95% CI, 0.36e1.00; p < 0.05) for female sex.
3.5. Orthostatic hypotension
An average of 8.83 (6.04) years from PD onset, 6.5% of patients
developed orthostatic hypotension that required treatment.
Notably,12.8% of late-onset patients had orthostatic hypotension by
the twelfth year compared to just 5.3% of early-onset patients. Lo-
gistic regression revealed that the OR was signiﬁcantly higher for
higher H & Y stages and patients without hypertension. The HRwas
1.039 (95% CI, 1.02e1.06; p < 0.01) for age at onset.
3.6. Psychosis
About 28.6% of patients had symptoms of psychosis an
average of 9.03 (5.38) years after PD onset. Interestingly, 53.9% of
late-onset patients and 22.1% of early-onset patients had expe-
rienced symptoms of psychosis by the twelfth year (p < 0.001).
Logistic regression tests revealed that the OR was signiﬁcantly
larger for higher H & Y stages and greater levodopa doses. The
HR was 1.05 (95% CI, 1.04e1.07; p < 0.001) for age of onset.Seventeen patients underwent ECT for the treatment of psy-
chotic symptoms that were refractory to medication. ECT took
place an average of 8.24 (6.07) years after PD onset. The preva-
lence rate for ECT was 1.8% in the twelfth year. More patients
with DM than without DM (3.8% vs. 1.0%) received ECT (p < 0.05).
Logistic regression revealed no OR effects for ECT (data not
shown).
3.7. Neuroleptic malignant syndrome
About 2.2% of patients developed neuroleptic malignant syn-
drome an average of 11.44 (7.79) years after PD onset. Among pa-
tients with DM, 9.0% developed malignant syndrome, whereas only
1.7% of patients without DM had experienced malignant syndrome
by the tenth year (p< 0.05). Logistic regression and HR assessments
did not reveal any risk factors that predisposed patients to devel-
oping malignant syndrome.
3.8. Pneumonia
About 4.3% of patients developed pneumonia, which occurred
an average of 13.87 (8.04) years after PD onset. Late-onset patients
(p < 0.001) and those with CVD (p < 0.001) were more likely to
develop pneumonia. The HR was 1.13 (95% CI, 1.09e1.16;
p < 0.001) for age at onset and 1.98 (95% CI, 1.03e3.80; p < 0.05)
for CVD. Tube feeding was necessary in 2.1% of patients after an
average of 16.03 (9.36) years after PD onset. Tube feeding preva-
lence rates were 0.1%, and 1.8% in the sixth and twelfth years,
respectively.
4. Discussion
In Western countries, the prevalence and incidence of PD are
greater in males than in females [12,13]. In our study, there were
more female patients, which is similar to what was previously re-
ported in a Japanese PD study (male:female, 1:1.2e1.7) [14,15]. In
this retrospective non-interventional study, we assessed symptom
prevalence and duration in a large cohort of Japanese patients with
PD. The duration to the onset of events, except for malignant syn-
drome, in the early-onset group was 1.5e2 times greater than that
in the late-onset group.
The questionnaire-based study by Chaudhuri et al. [16] revealed
no differences in pain rate (27% for patients with PD vs. 30.2% for
age matched-controls). Other studies have described higher pain
rates in patients with PD [17,18]; however, the studies utilized
different pain scales. We found that females and late-onset pa-
tients had increased pain rates, but other reports have stated that
younger age at onset [17] and female sex [19e21] were risk factors
for pain.
Female patients were more likely to experience wearing-off,
and the average female daily dose of levodopa was higher (11.5
(5.8) mg/kg compared to 8.8 (3.9) mg/kg for males; Fisher’s test,
p < 0.01). The DATATOP clinical trial showed that more females
developed dyskinesia and that this was likely due to the higher
amount of levodopa (p < 0.01) [22]. In our study, younger age at
onset was a risk for wearing-off. Which drug was prescribed ﬁrst
(levodopa or other drugs) did not affect wearing-off. A prospec-
tive study reported that motor complication prevalence was not
signiﬁcantly different between patients initially treated with
levodopa and those ﬁrst treated with DA [23e25]. Although there
were no statistical differences, the time without motor compli-
cations was longer in the group initially treated with DA; how-
ever, these patients often experienced sleepiness, edema, and
hallucinations [23e25]. In our 2002 study, the prevalence of
wearing-off was 21.3% at the ﬁfth year and 59.4% at the tenth year
A. Yoritaka et al. / Parkinsonism and Related Disorders 19 (2013) 725e731730from PD onset [15], which was slightly higher than what we
found here. In the interim between the studies, new anti-
parkinsonian drugs were marketed in Japan, including prami-
pexole (2004), ropinirole (2006), entacapone (2007), and zoni-
samide (2009). The availability of these drugs may have
prolonged wearing-off onset because we could select from
different DAs.
The prevalence of camptocormia and duration from PD onset to
camptocormia in our study were nearly identical to those previ-
ously described [26,27]. We found that female sex, older age at
onset, and disease severity were risk factors for camptocormia. In
our patient population, camptocormia was more severe during
walking or standing and tended to increase with fatigue and
decrease when non-ergot drug use was ceased. Camptocormia was
considered to be axial dystonia [28] rather than a myopathic
change [26,27]. Levodopa [29] or pramipexole [30] induced or
worsened camptocormia in some cases, but they may also have
beneﬁcial effects in cases in which it is due to PD. We investigated
the risk of camptocormia in patients with PD receiving non-ergot
DAs.
Sleep attack and excessive daytime sleepiness were more
common in males [31]. Disease duration, DA therapy, excessive
daytime sleepiness [32] and RBD [33] were risks of sleep attack.
Varying frequencies of sleep attack (0e43%) have been reported
[34].
A previous report showed that 60% of patients developed psy-
chosis during a 12-year study period [35]. The analysis revealed
that the risk of psychosis (mainly hallucinations) increased in pa-
tients with older age at onset and greater disease severity. In other
studies, older age [36] and longer disease duration [37,38] were
associated with psychosis, and disease severity was linked to the
presence of hallucinations [38]. Moreover, hallucinations were
more frequent among patients with early PD treated with DA
compared with thosewho received placebo or levodopa [39]. In our
study, patients with psychosis were treated with lower doses of
DAs and higher doses of levodopa, and other drugs were stopped
due to psychosis.
The risk of neuroleptic malignant syndrome has been previously
associated with CVD, cerebral contusion, physical stress [40],
infection, hot weather, and severe wearing-off [41]. In this study,
CVD was not a risk factor. Many patients experienced dehydration
or severe off-phases before neuroleptic malignant syndrome onset.
Although malignant syndrome and dopamine agonist withdrawal
syndrome [42] were both acute syndromes caused by a sudden
change in dopaminergic stimulation, the risk factors for these
syndromes were different.
Respiratory infection is one of the leading causes of death in
patients with PD [15]. Patients with late-onset PD or CVD were at
risk for developing pneumonia, and the mean duration of tube
feeding was 2 years after the ﬁrst episode of pneumonia.
The limitation of our retrospective study is that we did not
include patients who died early. Furthermore, this study was a
retrospective chart review study and certain treatment outcomes
differed from those of previously reported controlled prospective
studies.
NMSQuest studies [8,43] and the PRIAMO study [20] that used
self-completed NMS questionnaire have reported that NMS were
prevalent across all stages of PD disease. These studies broadly
included a broad spectrum of NMS that patients may not be aware
of as PD-related symptoms or clinicians ignored. However, until
recently, NMS were known to clinicians treating PD and patients
with PD, and many of the unrecognized NMS need treatment
because these reduce the quality of life.
In conclusion, we investigated the duration and prevalence rates
of various symptoms and complications in a large cohort of patientswith PD and determined that age and sexmight predict the onset of
some events. Moreover, the onset or duration of levodopa use
might inﬂuence the onset of wearing-off, but the order of levodopa
or other drugs did not predict symptoms.
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